Vetter can help you identify and develop the right packaging strategies for your compound, from clinical dev to commercialization to life cycle management.
Vetter’s decades of experience as a contract manufacturer providing fill & finish for injectable drugs helps deliver results for both large and small companies.
Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month.
Join us for a webinar on 8/18 to learn how Ology Biosciences is leveraging innovative technologies and expertise to bring vaccine production to the next level.
Despite FDA's postponement of most facility inspections, the pharma manufacturing industry should be prepared for heightened scrutiny as this crisis develops.
John J. Carney, Lee H. Rosebush, Susrut A. Carpenter, Andrew M. Serrao, BakerHostetler04.22.20